Sangamo BioSciences (SGMO)

Company Description

Sangamo BioSciences is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase II clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. SGMO’s other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington’s disease and hemoglobinopathies such as beta-thalassemia and sickle cell anemia. SGMO’s core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. The company has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington’s disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation.

 

COMPANY ADDRESS
501 Canal Boulevard
Richmond, California 94804
United States

COMPANY PHONE
510-970-6000

COMPANY WEBSITE



Get BioInvest's perspective on Sangamo's CEO


Latest Company News

What Type of Consensus Opinions Analysts hold about Sangamo Therapeutics, Inc ... Hot Stocks Point - 9 hours ago Sangamo Therapeutics, Inc. (SGMO) stock price ended its day with gain 5.00% and finalized at the price of $4.20. During its last trading session, Stock traded with the total exchanged volume of 0.46 million shares. [...]
Fri, Mar 24, 2017 4:52:00 PM, Continue reading at the source
Is Institutional Interest Waning in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)? Melville Review - 9 hours ago According to the latest company filings with the SEC, institutions owning shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have decreased their positions by -6.16%. [...]
Fri, Mar 24, 2017 4:07:00 PM, Continue reading at the source
Sangamo Therapeutics Inc (SGMO) Rating Reiterated by Cowen and Company The Cerbat Gem - 12 hours ago Sangamo Therapeutics Inc (NASDAQ:SGMO)'s stock had its “buy” rating restated by research analysts at Cowen and Company in a research report issued on Wednesday. The Sangamo Therapeutics Inc (SGMO) Receives Buy Rating from Cowen and Company - Petro Global News 24 Earnings And Analyst Opinion Offer Spending Insights: Blucora, Inc. (BCOR ... - Post Analyst [...]
Fri, Mar 24, 2017 1:07:00 PM, Continue reading at the source
Equity Perception: Analyst's Indicator Review for Sangamo Therapeutics, Inc ... The USA Commerce - Mar 23, 2017 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) dropped -1.23% to $4.00. During the trading on 03/22/2017, Company's stock ranged from $4.07 to $3.85. [...]
Thu, Mar 23, 2017 3:33:00 PM, Continue reading at the source
SANGAMO THERAPEUTICS, INC. (NASDAQ:SGMO) Files An 8-K Departure of Directors ... Market Exclusive - Mar 20, 2017 On March 14, 2017, the Compensation Committee of the Board of Directors of Sangamo Therapeutics, Inc. (the “Company”) adopted an Executive Severance Plan (the “Plan”). [...]
Mon, Mar 20, 2017 9:22:00 PM, Continue reading at the source
Sangamo Therapeutics Announces Presentation At The Cowen And Company 37th ... PR Newswire (press release) - Mar 1, 2017 RICHMOND, Calif., March 1, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B. [...]
Wed, Mar 01, 2017 9:00:00 PM, Continue reading at the source
Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-913 ... PR Newswire (press release) - Mar 1, 2017 RICHMOND, Calif., March 1, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that the U.S. [...]
Wed, Mar 01, 2017 1:33:00 PM, Continue reading at the source
Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results PR Newswire (press release) - Feb 28, 2017 "Early this year we rebranded our company as Sangamo Therapeutics, underscoring our focus on clinical development of genomic therapies using our industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy," ... SANGAMO THERAPEUTICS, INC. (NASDAQ:SGMO) Files An 8-K Results of Operations ... - Market Exclusive [...]
Tue, Feb 28, 2017 12:00:00 PM, Continue reading at the source
Sangamo Therapeutics Receives Rare Pediatric Disease Designation From FDA For ... PR Newswire (press release) - Feb 27, 2017 RICHMOND, Calif., Feb. 27, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, today announced that the U.S. Sangamo (SGMO) Announces Rare Pediatric Disease Designation From FDA For SB-318 - StreetInsider.com [...]
Mon, Feb 27, 2017 12:56:00 PM, Continue reading at the source
Sangamo Therapeutics Announces Fourth Quarter And Full Year 2016 Conference ... PR Newswire (press release) - Feb 21, 2017 RICHMOND, Calif., Feb. 21, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, announced today that the company will release its fourth quarter and full year 2016 financial results before the market ... [...]
Tue, Feb 21, 2017 9:04:00 PM, Continue reading at the source